Raltrox20 mg/2 ml

Raltrox is an opioid analgesic indicated for the following uses:

Established / FDA-approved uses

• Management of moderate to severe pain in patients for whom an opioid analgesic is appropriate and alternative treatments are inadequate.
• As a supplement to balanced general anesthesia during surgical procedures.
• For preoperative and postoperative analgesia.
• For obstetric analgesia during labor and delivery.

Off-label / adjunct uses (not FDA-approved indications)

• Treatment of opioid-induced pruritus (itching), such as itching related to epidural or intrathecal morphine, based on clinical experience and limited trial data; this use should only be undertaken under medical supervision.

The specific use of Raltrox in an individual patient should always be determined by a qualified physician.

Each mL of injectable solution contains Nalbuphine Hydrochloride equivalent to 10 mg or 20 mg of Nalbuphine base, in a sterile aqueous solution for parenteral administration. Formulations may also contain sodium citrate, citric acid, sodium metabisulfite (as a preservative/antioxidant in some products), and water for injection. Refer to the specific product label for exact excipients, as some formulations contain sulfites.

Raltrox is a synthetic opioid analgesic belonging to the phenanthrene class of agonist-antagonist opioids, chemically related to both naloxone (an opioid antagonist) and oxymorphone (an opioid agonist). It is used parenterally (by injection) for the relief of moderate to severe pain and as part of balanced anesthesia. Because of its mixed agonist-antagonist activity, Raltrox has a lower potential for abuse and a ceiling effect on respiratory depression compared with full opioid agonists such as morphine, although clinically significant respiratory depression can still occur, particularly when combined with other central nervous system depressants.

Raltrox belongs to the therapeutic class of opioid analgesics, specifically the opioid agonist-antagonist (mixed agonist-antagonist) subclass.

Mechanism of Action

Nalbuphine acts as a mixed opioid agonist-antagonist. It is a partial agonist/antagonist at the mu (μ) opioid receptor and an agonist at the kappa (κ) opioid receptor. This dual activity produces analgesia through kappa-receptor agonism while limiting mu-receptor-mediated effects such as euphoria and respiratory depression compared to pure mu-agonists, giving Nalbuphine a "ceiling effect" on respiratory depression at higher doses. Because of its antagonist activity at the mu-receptor, Nalbuphine can also reduce the analgesic and respiratory-depressant effects of concomitantly administered mu-agonist opioids and can precipitate withdrawal symptoms in patients physically dependent on full opioid agonists.

Pharmacokinetics

Raltrox injection is administered parenterally by subcutaneous, intramuscular, or slow intravenous injection, as directed by a physician or under medical supervision. It should be given by trained healthcare personnel with resuscitative equipment and opioid antagonists (e.g., naloxone) readily available, particularly when administered intravenously. Do not administer if the solution is discolored or contains particulate matter.

Clinically Significant Drug Interactions

• CNS depressants (benzodiazepines, sedatives, general anesthetics, alcohol): Concomitant use with Raltrox can cause profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients with no alternative, use the lowest effective doses, and monitor closely.
• Monoamine oxidase inhibitors (MAOIs): Concurrent use of Raltrox with MAOIs or within 14 days of stopping an MAOI is not recommended due to risk of unpredictable, potentially severe CNS and respiratory reactions.
• Other opioid agonists (e.g., morphine, fentanyl) or in opioid-dependent patients: Because of its antagonist activity, Raltrox can precipitate acute withdrawal symptoms in patients who are physically dependent on full opioid agonists, and it can reduce the analgesic effect of previously or concurrently administered full agonist opioids.
• Serotonergic drugs (e.g., SSRIs, SNRIs, triptans): Combination with Raltrox may increase the risk of serotonin syndrome.
• Muscle relaxants: Raltrox may enhance neuromuscular blockade and increase the degree of respiratory depression.

Common Side Effects

• Sedation/drowsiness (most common)
• Dizziness or vertigo
• Nausea and vomiting
• Dry mouth
• Headache
• Sweating, clammy skin, or flushing
• Itching

Serious Side Effects

• Respiratory depression (dose-related; Raltrox exhibits a ceiling effect on respiratory depression at higher doses compared with full opioid agonists, but clinically significant depression can still occur, especially with concurrent CNS depressants).
• Severe hypotension and syncope
• Anaphylaxis and other hypersensitivity reactions
• Seizures (in susceptible patients)
• Physical dependence and withdrawal symptoms with prolonged use, or precipitated withdrawal in opioid-dependent patients (see Precautions and Warnings)

Patients should seek urgent medical attention for difficulty breathing, extreme drowsiness, or fainting after receiving Raltrox.

Pregnancy

Raltrox should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close medical supervision. When used during labor and delivery, Raltrox has been associated with severe fetal bradycardia and neonatal respiratory depression; continuous fetal monitoring is advised. Prolonged use of Raltrox during pregnancy may result in neonatal opioid withdrawal syndrome in the newborn, which can be life-threatening if not recognized and treated appropriately. Consult a physician before using Raltrox at any stage of pregnancy.

Lactation

Raltrox is excreted into breast milk in small amounts. Breastfeeding is generally not recommended during treatment with Raltrox unless a physician determines the benefit outweighs the risk, given the potential for sedation and respiratory depression in the nursing infant; monitor the infant closely if maternal use continues.

Respiratory Depression

Serious, life-threatening, or fatal respiratory depression can occur with Raltrox, especially during initiation of therapy or after a dose increase. Monitor closely, particularly within the first 24-72 hours.

Risk with Concomitant CNS Depressants

Concomitant use of Raltrox with benzodiazepines, other sedatives, or alcohol can result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternatives are inadequate.

Precipitated Withdrawal in Opioid-Dependent Patients

Because Raltrox has antagonist activity at the mu-opioid receptor, it can precipitate acute withdrawal symptoms (e.g., anxiety, agitation, sweating, tachycardia, abdominal cramps) if given to a patient who is physically dependent on a full opioid agonist (such as morphine or heroin). Assess opioid use history carefully before administering Raltrox to such patients.

Abuse, Misuse, and Dependence

Raltrox carries a risk of addiction, abuse, and misuse, which can lead to overdose and death. Use the lowest effective dose for the shortest duration consistent with treatment goals. Do not exceed the prescribed dose or duration, and do not share Raltrox with any other person.

Other Precautions

• Use with caution in patients with head injury or increased intracranial pressure, as Raltrox may obscure clinical signs and further elevate intracranial pressure.
• Use with caution in patients with hepatic or renal impairment due to reduced clearance.
• Use with caution in patients with cardiac disease, as opioids can cause hypotension.
• May impair mental or physical abilities; advise patients not to drive or operate machinery until they know how Raltrox affects them.
• Adrenal insufficiency has been reported with opioid use, including Raltrox, particularly with use beyond one month.

Overdose of Raltrox is a medical emergency. Signs and symptoms may include severe respiratory depression, extreme drowsiness progressing to stupor or coma, pinpoint pupils, cold and clammy skin, and skeletal muscle flaccidity. In severe cases, apnea, cardiovascular collapse, and death can occur.

If overdose with Raltrox is suspected, seek immediate emergency medical attention or contact a poison control center right away. Management involves establishing and maintaining a patent airway, assisted or controlled ventilation, and administration of an opioid antagonist (e.g., naloxone) by trained medical personnel, with close monitoring since the antagonist's effect may wear off before that of Raltrox. Do not attempt to manage a suspected overdose at home without professional medical guidance.

Store at room temperature (20-25°C / 68-77°F; excursions permitted between 15-30°C), away from light and moisture. Keep out of reach of children. Do not use if the solution is discolored or contains particles.

Pediatric Use

Safety and efficacy of Raltrox in patients under 18 years of age have not been well established in controlled trials; use only under specialist medical supervision when the benefit is judged to outweigh the risk.

Geriatric Use

Elderly patients may be more sensitive to the sedative and respiratory-depressant effects of Raltrox. Start with a lower dose and titrate cautiously, monitoring closely for adverse effects.

Renal Impairment

Use Raltrox with caution and consider dose reduction, as impaired renal function can prolong drug elimination and increase the risk of toxicity.

Hepatic Impairment

Use Raltrox with caution and consider dose reduction in patients with significant hepatic impairment due to reduced metabolic clearance.

Opioid-Tolerant or Dependent Patients

See Precautions and Warnings regarding the risk of precipitated withdrawal.

Raltrox is generally used for short-term management of acute pain, anesthesia support, or labor analgesia, typically for the shortest duration necessary to achieve treatment goals. Prolonged or repeated use should be reassessed regularly by a physician because of the risk of tolerance, physical dependence, and adrenal insufficiency with extended use.

Opioid analgesics; Agonist-antagonist opioids (mixed opioid agonist-antagonist analgesics).

Nalbuphine exerts its analgesic effect primarily as an agonist at kappa (κ) opioid receptors, combined with partial agonist/antagonist activity at mu (μ) opioid receptors. This mixed receptor profile provides effective analgesia while producing a ceiling effect on respiratory depression and lower abuse liability compared with pure mu-agonist opioids. See Pharmacology for full pharmacokinetic details.

B (legacy FDA pregnancy category from earlier labeling conventions; current prescribing information uses narrative, risk-based labeling instead of letter categories and recommends use only if the potential benefit justifies the potential risk to the fetus)

The safety and effectiveness of Raltrox in pediatric patients have not been established through adequate, well-controlled clinical trials. Limited data suggest possible use for postoperative analgesia under close specialist supervision, but Raltrox should generally not be used in children outside a hospital setting without direct physician guidance, and neonates and infants may be particularly sensitive to respiratory depression.